

Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer

WEIMIN FAN^{1,2}, XUE YANG², FANG HUANG³, XIANGMIN TONG², LIFEN ZHU² and SHIBING WANG²

¹The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000;

²Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014; ³Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Received December 4, 2018; Accepted June 13, 2019

DOI: 10.3892/ol.2019.10673

Abstract. The mannose receptor (CD206) functions in endocytosis and phagocytosis, and plays an important role in immune homeostasis. Tumor-associated macrophages express high level of CD206 and are thought to contribute to cancer progression through tumor immunosuppression, metastasis and angiogenesis. However, the significance of CD206 in the pathology of liver cancer has not been investigated. The present study evaluated the clinical significance of CD206 in the progression and prognosis of liver cancer in pathological tissues from 327 patients. Increased CD206 expression was observed in liver cancer samples compared with healthy adjacent liver tissue (42.8 vs. 62.4%; $P < 0.05$). CD206 expression was significantly associated with tumor size ($P = 0.009$) and metastasis ($P = 0.041$). The recurrence free survival rate of patients with CD206-positive liver cancer was significantly decreased compared with patients with CD206-negative liver cancer ($P = 0.003$). A Cox regression model revealed that liver cancer survival was independently associated with tumor size, metastasis and α -fetoprotein value. The results further revealed that CD206 expression in cancer stem cell (CSC)-like cells was comparable to other internationally recognized biomarkers. Additionally, when CD206 expression was silenced in the liver cancer cell lines HepG2 and PLC/PRF/5 using a short hairpin RNA approach, migration and invasion of the cells significantly decreased compared with controls ($P < 0.01$). CD206 expression in liver cancer significantly influences distant metastasis and spread, resulting in poor patient

prognosis. Furthermore, CD206 may be a potential biomarker in CSC-like cells to predict the occurrence of liver cancer.

Introduction

Liver cancer had the seventh highest age-adjusted incidence rate of all types of cancer in the United States of America in 2014, often with high mortality (1-3). Liver cancer requires the detection of small tumors that are often present in asymptomatic individuals (4). Liver cancer is diagnosed by imaging modalities, including computerized tomography and magnetic resonance imaging scans, followed by confirmation via liver biopsy, an invasive procedure (5-7). Although the diagnosis of liver cancer has improved rapidly in recent years, $< 5\%$ of patients with liver cancer survive > 5 years following diagnosis (8,9). Previous studies suggest that high invasiveness and metastasis are the main causes of poor prognosis (10,11). Early liver cancer diagnosis is of paramount importance to therapy and more effective biomarkers to predict the clinical outcome of liver cancer are required.

The mannose receptor (CD206), also known as C-type lectin, is expressed on the surface of macrophages and some subsets of immature dendritic cells (12). CD206 participates in antigen presentation, macrophage endocytosis and is considered a hallmark of tumor-associated macrophages (13). CD206 increased the growth and migration of microglia by promoting their activation (14). Additionally, CD206 expressed on lymphatic endothelium participates in the attachment of various cancer cells to lymphatic endothelium to promote lymphatic metastasis (15-17). Serum CD206 is elevated in patients with multiple myeloma and is a prognostic marker for overall survival (18,19). Furthermore, CD206 has been reported as a novel biomarker for the diagnosis of patients with colorectal and gastric cancer (20,21). Therefore, the investigation of the potential role of CD206 in liver cancer may be beneficial to patients.

The present study evaluated the clinical significance of CD206 in the progression and prognosis of liver cancer. A suspension culture was used to enrich liver cancer stem cell (CSC)-like cells, which acquire the properties of liver CSCs in term of self-renewal, differentiation, quiescence, chemo-resistance and tumorigenicity (22,23). The results obtained

Correspondence to: Dr Lifan Zhu or Dr Shibing Wang, Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road, Hangzhou, Zhejiang 310000, P.R. China
E-mail: zlf892466@163.com
E-mail: wangshibing@hmc.edu.cn

Key words: mannose receptor, liver cancer, cancer stem cells, biomarker, prognosis

indicated that CD206 may act as a biomarker in CSC-like cells to predict liver cancer occurrence. CD206 promoted the motility and invasiveness of liver cancer cell lines *in vitro*. Furthermore, it was revealed that the upregulation of CD206 in liver cancer contributes to poor patient prognosis. Thus, novel therapeutic agents targeting CD206 may be beneficial for patients with liver cancer.

Materials and methods

Liver cancer samples and cell lines. The tissue microarrays (TMAs) used in the current study were purchased from Shanghai Biochip Co. Ltd. Written informed consent was obtained from all the patients and the protocol was approved by the Medical Ethics Review Committee of the Zhejiang Provincial People's Hospital. The experiment began in August 2013 and ended in August 2018. The inclusion criteria were as follows: i) diagnosis of hepatocellular carcinoma, ii) patients who signed informed consent and iii) patients with adequate hepatocellular carcinoma tissue to make tissue microarrays (cylindrical liver cancer tissue at least 1 mm in diameter and 1 mm in length). In the tissue microarrays, all the patients had complete clinical data. A total of 327 patients with liver cancer were divided into the following groups according to their respective characteristics: i) age (<55 or ≥55 years) (24), ii) gender (male or female), iii) tumor size (diameter <5 or ≥5 cm) (25), iv) tumor number (single or multiple) (26), v) Edmondson Grade (I+II or III) (27), vi) metastasis (M0 or M1) (28), vii) micro-vascular invasion (absent or present) (29,30), viii) Hepatitis B virus antigen (negative or positive) (31), ix) cirrhosis (negative or positive) (32) and x) α-fetoprotein (AFP; <20 or ≥20 μg/l) (33). The patients included 266 males and 61 females (age range, 31-83 years; median, 57.5 years). All the patients had follow-up records for 60 months. Survival time was calculated from the date of surgery to the deadline of 60 months. The liver cancer cell lines HepG2 and PLC/PRF/5 (Chinese Academy of Sciences) were cultured in medium DMEM (HyClone; GE Healthcare Life Sciences), containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 1% penicillin-streptomycin and 0.5% glutamine (2 mM) at 37°C in a humidified atmosphere (95% air and 5% CO₂).

Immunohistochemical staining. The hepatocellular carcinoma tissue samples were fixed in 10% formalin for 24 h at 26°C and paraffin embedded. Histological sections were cut into 4 μm and stored at 4°C. The sections were dried for 2 h in an oven preheated to 65°C and dewaxed using xylene and standard procedures using graded alcohol at 37°C for 10 min each time for three times. Antigen retrieval was performed by heating the sections in citrate buffer (pH=6.0; 0.01 M) at 180°C for 3 min. Endogenous peroxidase activity was inhibited by 3% hydrogen peroxide solution at 37°C for 15 min. Sections were blocked using goat serum (cat. no. 31430; 1:500; Thermo Fisher Scientific, Inc.) to prevent non-specific binding for 15 min at 37°C. Rabbit anti-CD206 primary monoclonal antibody (cat. no. ab64693; 1:400; Abcam) was used to incubate the sections at 4°C overnight. Following three washes with PBS, the biotin-labeled rabbit antibody (cat. no. 31402; 1:500; Thermo Fisher Scientific, Inc.) was used as a secondary

antibody and incubated with sections. Horseradish enzyme labeled streptomycin albumen (Thermo Fisher Scientific, Inc.) was subsequently incubated for 0.5 h at 37°C. TMAs were stained with 3,3'-diaminobenzidine (Fuzhou Maixin Biotech Co., Ltd.) for 15 min at 37°C and counterstained with hematoxylin for 15 sec at 37°C. The sections were dehydrated at 37°C as follows: 75% alcohol immersion for 3 min, 85% alcohol immersion for 3 min, 95% alcohol immersion for 3 min, absolute alcohol immersion for 5 min and two rounds of xylene immersion for 5 min. The sections were dried, covered with neutral gum and mounted. The sections were observed using a fluorescence microscope (magnification, x400).

Staining patterns and evaluation. The degree of CD206 immunostaining was evaluated blindly by three pathologists. CD206 expression evaluation was based on the intensity of stained tumor cells. A total of five fields of view were randomly selected in each microarray. Scores were used to represent the intensity of the staining in the cytoplasm or membrane in the microarrays. '0' was non-stained, '1' was weakly stained as light yellow, '2' was moderately stained as brown and '3' was heavily stained as dark brown. In total, five fields of view were observed and scored according to the aforementioned rules. CD206 scores were calculated with scores of 0-5 and 6-12 representing the low and high expression groups, respectively.

Sphere culture and sphere passage. PLC/PRF/5 cells were resuspended to a cell density of 5000 cells/ml, washed to remove serum and suspended in serum-free DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20 ng/ml human recombinant basic fibroblast growth factor (Merck KGaA), 20 ng/ml human recombinant epidermal growth factor (Merck KGaA), 2% B27 supplement without vitamin A (Gibco; Thermo Fisher Scientific, Inc.), 100 IU/ml penicillin and 100 μg/ml of streptomycin in ultra-low attachment 6-well plates (Corning Inc.). Fresh DMEM/F12 with 20 ng/ml human recombinant basic fibroblast growth factor, 20 ng/ml human recombinant epidermal growth factor, 2% B27 was added to the ultra-low attachment plates every two days. Four days later, the tumor spheres were collected by gentle centrifugation with 100 x g for 4 min at 37°C and digested by Accutase (Sigma-Aldrich; Merck KGaA) for 5 min at 37°C to form a single cell suspension for subsequent experiments. Tumor spheres were centrifuged with 100 x g for 3 min at 37°C to remove the enzyme and resuspended with 20 ng/ml human recombinant basic fibroblast growth factor, 20 ng/ml human recombinant epidermal growth factor and 2% B27 in ultra-low attachment 6-well plates (Corning Inc.) and allowed to reform spheres. The spheres were passaged every 4 days.

Reverse-transcription quantitative polymerase chain reaction (RT-qPCR). HepG2 and PLC/PRF/5 cells transfected with shCD206 and shNC were washed three times with PBS, and the total RNA was extracted using Trizol (Invitrogen; Thermo Fisher Scientific, Inc.). The extracted RNA was reverse-transcribed into cDNA using PrimeScript™ 1st Strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd.). qPCR was performed using a KAPA SYBR Green qPCR kit (Roche Diagnostics). The following primer pairs were used: CD206 forward, 5'-GCAGAAGGAGTAACCCACCC-3' and reverse,

5'-TGGCAAATGAAGGCGTTTGG-3'; Nanog homeobox (Nanog) forward, 5'-AAGGCCTCAGCACCTACCTA-3' and reverse, 5'-ACATTAAGGCCTTCCCCAGC-3'; POU class 5 homeobox 1 (Oct4) forward, 5'-GCCCCGAAAGAGAAAGCGAAC-3' and reverse, 5'-AACCACACTCGGACCACTCG-3'; SRY-box 2 (Sox2) forward, 5'-TTTGTCTGGAGACGGAGAAGC-3' and reverse, 5'-TAACTGTCCATGCGCTGGTT-3'; MYC-binding protein (c-Myc) forward, 5'-GCATACATCCTGTCCGTCCA-3' and reverse, 5'-CGTCGTTTCCGCAACAAGTC-3'; CD44 molecule (CD44) forward, 5'-AGCAACTGAGACAGCAACCA-3' and reverse, 5'-CGTACCAGCATTGTGTGTTGT-3' and GAPDH forward, 5'-GCTCCCTCTTCTTTGCAGC-3' and reverse, 5'-GTTGTCATGGATGACCTTGGC-3'. The following thermocycling conditions were used: Pre-denaturing at 95°C for 5 min, 35 cycles of 95°C for 10 sec, 60°C for 30 sec and, 72°C for 30 sec and extension at 72°C for 10 min. mRNA levels were quantified using the 2^{-ΔΔC_q} method (20) and normalized to GAPDH. RT-qPCR was performed in triplicate.

Transfection. The short hairpin (sh) CD206 (5'-GCAGAA GGAGTAACCCACCC-3') and sh negative control (NC) (5'-GATCCGACTTCATAAGGCTTC-3') were purchased from GeneCopoeia, Inc. The QIAGEN Plasmid Mini kit (Qiagen GmbH), EndoFectin-Lenti™ (GeneCopoeia, Inc.) and TiterBoost™ reagents (GeneCopoeia, Inc.) were used to generate plasmids delivering shNC and shCD206. The plasmids were co-transfected into 293Ta cells (Chinese Academy of Sciences) with Lenti-Pac™ HIV packaging mix (cat. no. HPK-LvTR-20, GeneCopoeia, Inc.). The lentiviral particles were purified by centrifugation at 3,500 x g and 4°C for 25 min. Lentiviral particles were stored at -80°C until use. HepG2 and PLC/PRF/5 cells seeded in 24-well plate (1x10⁵ cells/well). The lenti-shCD206 and lenti-shNC were used to transfect HepG2 and PLC/PRF/5 cell at a multiplicity of infection of 30. DMEM was replaced 24 h following transfection. Puromycin at 1-10 μg/ml was used to screen the HepG2 and PLC/PRF/5 cells stably expressing shNC and shCD206.

Western blot analysis. HepG2 and PLC/PRF/5 cells stably expressing shCD206 or shNC were lysed using lysis buffer (Beyotime Institute of Biotechnology), 1% complete mini-protease inhibitor cocktail (Roche Diagnostics) and 5 mM sodium fluoride. The total protein was quantified using a bicinchoninic acid assay (Thermo Fisher Scientific, Inc.) and heated for 10 min at 100°C. A total of 30 μg protein/lane was separated via SDS-PAGE on a 12% gel and transferred to a nitrocellulose membrane (Merck KGaA). The membrane was blocked for 1 h at 37°C and immunoblotted with primary antibodies against CD206 (cat. no. ab8918; 1:1,000; Abcam), Nanog (cat. no. ab109250; 1:1,000; Abcam), Oct4 (cat. no. ab18976; 1:1,000; Abcam), Sox2 (cat. no. ab79351; 1:1,000; Abcam), c-Myc (cat. no. ab39688; 1:1,000; Abcam), CD44 (cat. no. ab189524; 1:1,000; Abcam) and GAPDH (cat. no. ab9485; 1:5,000; Abcam) overnight at 4°C. Membranes were subsequently washed with TBST and incubated with horseradish peroxidase-conjugated goat anti-rabbit (cat. no. HA1001; 1:50,000; HuaBio) or anti-mouse antibodies (cat. no. HA1006; 1:5,000; HuaBio) for 1 h at room temperature. Protein bands were detected using a ChemiDoc™ MP

Imaging system (Bio-Rad Laboratories, Inc.) with a super enhanced chemiluminescence detection kit (Applygen Technologies, Inc.).

Wound healing assay. HepG2 and PLC/PRF/5 cells transfected with lenti-shNC and lenti-shCD206 were seeded on separate 6-well plates at a concentration of 1x10⁶ cells/ml. When the liver cancer cells reached ~90% confluence, a marker pen was used to draw a horizontal line on the bottom of the 6-well plates. A cross was drawn every 0.5 cm and 5 lines were drawn across each well. A 20 μl pipette tip was used to scratch the cell layer perpendicular to the horizontal lines. PBS was used to wash the cells three times and serum-free DMEM was added into the plates. The cells were cultured at 37°C with 5% CO₂ for 24 h. Images at 5 fields of view were taken and migration as calculated as follows: (Width of the scratch at 0 h-width of the scratch at 24 h)/width of the scratch at 0 h x100%.

Cell invasion assay. HepG2 and PLC/PRF/5 cells transfected with shCD206 and shNC were serum starved for 24 h prior to the invasion assay. Transwell inserts were placed into 24-well plates, 24-well transwell plate (8.0 μm pore size; Corning Inc.) coated with 20 μg Matrigel and incubated for 120 min at 37°C to promote uniform gel formation. A total of 100 μl cell suspension at a concentration of 3x10⁴ cells/ml was added to the upper chamber, and 500 μl 10% FBS-DMEM medium containing cells transfected with shCD206 or shNC were added to the lower chamber. In the control group, 500 μl 10% FCS-DMEM medium was added to lower chamber. Following incubation for 48 h at 37°C with 5% CO₂, the cells were fixed with 4% formaldehyde at 37°C for 15 min. Cells were stained with 0.5% crystal violet dye at 37°C for 10 min. Cells on the Matrigel and microporous membrane layer were removed using a cotton swab and cells which invaded the lower microporous membrane were retained. The number of cells in five randomly selected fields of view was counted using an inverted light microscope (magnification, x100).

Statistical analysis. The Statistical Package for the Social Sciences (version 13.0; SPSS Inc.) was used for statistical analysis. Data are presented as the mean ± standard deviation. For comparison between 2 groups, significant differences were determined using the Student's t-test or Wilcoxon rank test. The χ^2 or Fisher exact tests were used to assess CD206 expression in patients with HCC. The Kaplan-Meier method and the log-rank test were used to analyze survival curves. The multivariate Cox proportional hazards regression model was used to analyze the univariate factors with prognostic significance in HCC. P<0.05 was considered to indicate a statistically significant difference.

Results

CD206 expression in liver cancer samples and healthy tissue. Immunohistochemical methods were used to assess the expression of CD206 in liver cancer tissue. The staining for CD206 was observed predominantly in the membrane and cytoplasm of liver cancer cells. Three pathologists independently evaluated the liver cancer tissue microarrays under x40 (Fig. 1A, C, E and G) and x200 magnification




Figure 1. CD206 staining in liver cancer and healthy adjacent tissues. Low expression of CD206 in normal tissue (score=0-5), magnification (A) x40 and (B) x200. High expression of CD206 in normal tissue (score=6-12), magnification (C) x40 and (D) x200. Low expression of CD206 in liver cancer tissue (score=4), magnification (E) x40 and (F) x200. High expression of CD206 in liver cancer tissue (score=16), magnification (G) x40 and (H) x200. (I) Association between CD206 expression and survival time. CD206, mannose receptor. $P<0.01$, as indicated.

(Fig. 1B, D, F and H). CD206 showed positive expression in the cell membrane and cytoplasm of liver cancer cells. High levels of CD206 expression were detected in 204/327 (62.4%) of the patients with liver cancer. Positive expression was observed in adjacent healthy liver tissue (5 mm from the liver tumor and histopathologically confirmed) in 140/327 (42.8%) patients. Upon dividing samples into high expression (>6 points) and low expression groups (0-5 points), the expression value of CD206 in liver cancer tissues was 7.69 ± 3.11 points, and the expression value of CD206 in adjacent healthy liver tissue was 3.60 ± 2.17 points ($P<0.05$). Taken together, these data demonstrated elevated CD206 expression in liver cancer tumors.

Patient characteristics and the association between CD206 expression, liver cancer clinicopathological features and prognosis. The present study investigated whether CD206 expression is associated with the progression of liver cancer. CD206 immunopositivity was not associated with gender, age, tumor number, Edmondson grade, microvascular invasion, hepatitis B virus antigen, cirrhosis and AFP (Table I). The survival time for patients with CD206-negative liver cancer was 51.517 ± 1.781 months and was significantly increased compared with patients with CD206-positive liver cancer (46.067 ± 2.183 months). The Kaplan-Meier survival curves indicated that CD206 expression was significantly associated with overall survival in patients with liver cancer ($P=0.003$; Fig. 1I). Additionally, prognosis factors in liver cancer were

analyzed by Cox-regression analysis. CD206 positivity was significantly associated with tumor size ($P=0.039$), metastasis ($P=0.022$) and AFP value ($P=0.002$). There was no statistically significant association between CD206 expression and gender ($P>0.05$), age ($P>0.05$), cirrhosis ($P>0.05$), metastasis ($P>0.05$), AFP ($P>0.05$) and tumor number ($P>0.05$) as demonstrated by multivariate analysis (Table II). However, CD206 was significantly associated with the Edmondson grade ($P=0.009$).

CD206 as a biomarker in cancer stem cells may be used to predict liver cancer. The suspension culture in growth factor-defined serum-free medium may be used to enrich cells associated with the traits of CSCs (34,35). To validate whether liver cancer cell lines acquire these traits when passed through the suspension culture, the liver cancer cell line PLC/PRF/5 was subjected to specific serum-free medium. In ultra-low attachment plates, PLC/PRF/5 gradually formed non-adherent spheroid bodies, termed sphere cells, following culture for 4-6 days (Fig. 2A). RT-qPCR was used to assess the expression of recognized biomarker genes (Nanog, Oct4, Sox2, c-Myc and CD44) and CD206 in the CSC spheres and the parent cells from which they were derived (36-38). The results revealed that, although the mRNA levels of CD206 did not increase to the same levels as Nanog, CD44 and Sox2, CD206 expression was comparable to Oct4, and was significantly increased compared with c-Myc (Fig. 2B). These results were validated at the protein level through western blot analysis, where

Table I. Expression of CD206 in liver cancer tissue.

Clinical parameter	Number	CD206 expression		χ^2	P-value
		Low	High		
Age (years)				1.601	0.206
<55	126	42	84		
≥55	201	81	120		
Gender				0.745	0.388
Male	266	103	163		
Female	61	20	41		
Size ^a				6.913	0.009
<5	191	83	108		
≥5	128	37	81		
Tumour number				0.003	0.956
Single	269	101	168		
Multiple	58	22	36		
Edmondson grade ^a				3.771	0.052
I+II	202	68	134		
III	119	53	66		
Metastasis ^a				4.159	0.041
M0	294	105	189		
M1	27	15	12		
Microvascular invasion ^a				0.118	0.732
Absence	122	49	73		
Presence	121	46	75		
Hepatitis B virus antigen ^a				3.101	0.078
Negative	62	29	3		
Positive	259	90	169		
Cirrhosis				0.008	0.928
Negative	110	41	69		
Positive	217	82	135		
α-fetoprotein ^a				0.090	0.764
<20	143	49	94		
≥20	123	40	83		

^aTotal number was <327 due to incomplete pathological data.

increased expression of CD206 was observed in the sphere cells compared with the parent cells (Fig. 2C). Taken together, these data suggest that CD206, similar to the biomarkers Nanog, CD44, Sox2, Oct4 and c-Myc, has the potential to predict cancer occurrence and progression in CSC-like cells.

CD206 silencing decreases liver cancer cell motility and invasion. To assess the role of CD206 in liver cancer cell migration and invasion, HepG2 and PLC/PRF/5 cells were infected with lentiviruses expressing CD206 shRNA (shCD206) or a scrambled sequence (shNC) to obtain stable expression cell lines. CD206 silencing following shCD206 lentiviral transfection was confirmed by Western Blot analysis (Fig. 3A). Migration (Fig. 3B and C) and invasion assays (Fig. 3D and E) revealed that CD206 silencing significantly decreased HepG2 and PLC/PRF/5 cell migration and invasion compared with

the shNC group ($P<0.05$). These observations indicated that CD206 promotes the motility and invasiveness of liver cancer cell lines.

Discussion

Liver cancer is a multigene disease characterized by a high degree of malignancy, rapid development, low survival rates and late detection (9,39). Surgical interventions are often ineffective due to late diagnosis (40). Novel liver cancer diagnostic and therapeutic targets are therefore required.

CD206 is a pattern recognition receptor that identifies the extracellular domains of specific carbohydrate molecules and is highly expressed on the surface of macrophages and immature dendritic cells (41). In the present study, CD206 was expressed in the cytoplasm and on the plasma membrane of liver cancer

Table II. Univariate and multivariate Cox regression analysis of the clinicopathological parameters in patients with liver cancer.

Parameter	Number	Univariate analysis				Multivariate analysis			
		Regression coefficient	HR	95% CI	P-value	Regression coefficient	HR	95.0% CI	P-value
Sex (male/female)	266/61	-0.124	0.883	0.556-1.403	0.598	-0.186	0.830	0.371-1.857	0.650
Age (<55/≥55 years)	126/201	-0.027	0.973	0.571-1.658	0.920	-0.493	0.611	0.289-1.293	0.198
Tumor size (<50/≥50 mm) ^a	191/128	0.489	1.630	1.025-2.592	0.039	0.254	1.289	0.557-2.982	0.553
Tumor number (single/multiple) ^a	268/58	0.059	1.060	0.582-1.933	0.848	1.008	2.740	1.051-7.143	0.039
Edmondson grade (I+II/III) ^a	202/119	0.455	1.577	0.989-2.515	0.056	1.021	2.775	1.291-5.965	0.009
Metastasis (M0/M1) ^a	294/27	0.160	1.173	0.629-2.188	0.022	1.293	3.644	1.314-10.104	0.013
Microvascular invasion (-/+) ^a	122/121	0.606	1.834	1.089-3.087	0.615	0.310	1.364	0.578-3.219	0.479
Hepatitis B virus (-/+) ^a	62/259	0.002	1.002	0.558-1.800	0.994	-0.526	0.591	0.180-1.937	0.385
Cirrhosis (-/+)	110/217	-0.283	0.754	0.456-1.247	0.271	0.901	2.463	0.912-6.655	0.076
α-fetoprotein (<20/≥20 μg/l) ^a	143/123	0.920	2.510	1.395-4.517	0.002	0.647	1.910	0.855-4.264	0.114

^aTotal number was <327 due to incomplete pathological data. HR, hazard ratio; CI, confidence interval.




Figure 2. CD206 is a biomarker in cancer stem cells to predict the progression of liver cancer. (A) The liver cancer cell line PLC/PRF/5 formed sphere bodies in suspension culture/ (B) mRNA levels of Nanog, Oct4, Sox2, c-Myc, CD44 and CD206. * $P < 0.05$, ** $P < 0.01$ vs. PLC/PRF/5 parents. (C) The expression level of CD206 increased in a similar manner to the expression of the internationally recognized biomarker proteins Nanog, Oct4, Sox2, c-Myc and CD44. CD206, mannose receptor; Nanog, Nanog homeobox; Oct4, POU class 5 homeobox 1; Sox2, SRY-box 2; c-Myc, MYC binding protein; CD44, CD44 molecule.

cells. Additionally, CD206 upregulation was observed in liver cancer tissue compared with healthy adjacent tissue obtained from patients with liver cancer. CD206 expression was not significantly associated with gender, age, tumor number, Edmondson grade, microvascular invasion, hepatitis B virus

antigen and cirrhosis, but had a positive association with tumor size, metastasis and the AFP value. The present study therefore demonstrated a preliminary association between CD206 and the occurrence and development of liver cancer. Previous studies investigating liver cancer-associated proteins have demonstrated an association between marker expression and cancer staging. The present study revealed that CD206 expression was associated with tumor size, metastasis and the AFP value, indicating that its expression is associated with poor liver cancer prognosis. Furthermore, the association between CD206 expression and survival time revealed that the levels of CD206 were positively associated with poor prognosis. Taken together, these data suggested that high CD206 expression promotes the rapid growth and metastasis of liver cancer.

Uncontrolled self-renewal directly contributes to the progression of liver cancer and other types of carcinomas. The same molecular pathways that regulate self-renewal in normal stem cells also control CSCs (22,38,42). The present study revealed that CD206 is an important biomarker for liver cancer progression in CSCs, similar to other known markers including Nanog, Oct4, Sox2, c-Myc and CD44 (15,43-46). The expression of these markers in CSCs are recognized as evidence of stem cell carcinogenesis (37,47,48). The present study detected the expression levels of CD206 in CSCs and demonstrated high expression at both the mRNA and protein levels, which were comparable with the levels of Oct4 and c-Myc. The results obtained in the current study suggested that CD206 may be used as a biomarker in CSCs to predict liver cancer, highlighting its diagnostic value.

The present study investigated the direct effects of CD206 knockdown on liver cancer cells lines. The migration and invasion abilities of liver cancer cells decreased when CD206 was silenced, suggesting that high CD206 expression levels promote tumor metastasis and poor prognosis in patients.

Hepatitis C virus (HCV) infection is a main cause of liver cancer (49,50). However, the present study did not investigate




Figure 3. Decreased cell migration and invasion following CD206 silencing in HepG2 and PLC/PRF/5 cells. (A) Western blot analysis demonstrating that CD206 expression was reduced following shCD206 transfection. (B) Significant impairment of cell migration in HepG2 and PLC/PRF/5 cells transfected with shCD206 compared with controls was observed. (C) Quantification of the migration of shCD206 transfected cells demonstrating that cell migration was significantly decreased compared with controls. (D) Significant reduction in invasion was observed in HepG2 and PLC/PRF/5 cells transfected with shCD206 compared with shNC controls. (E) Quantification of the invasion of shCD206 transfected cells, indicating reduced invasiveness compared with controls. ** $P < 0.01$ vs. shNC treatment. CD206, mannose receptor; sh, short hair; NC, negative control.

the important role of HCV infection in liver cancer and this is a limitation of the study. Future studies investigating the association between HCV infection and CD206 expression are required.

In summary, the present study revealed that CD206 may be used as a diagnostic tool to screen for liver cancer, and its

upregulation in liver tumors represents a therapeutic target to reduce liver cancer cell metastasis. Future investigation of the efficacy of CD206 inhibitors on liver cancer cells as well as an evaluation of the potential toxic effects on normal hepatocytes is required. Such studies may lay the theoretical foundations for future clinical liver cancer diagnosis and treatment.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Science Foundation of China (grant nos. 81602706 and 81570198), Zhejiang Medical Technology Plan Project (grant no. WKJ-ZJ-1709) and the State Administration of Traditional Chinese Medicine of Zhejiang (grant nos. 2016ZZ007 and 2017ZB006).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

SW, LZ and XT conceived and designed the study. WF, XY and FH performed the experiments. SW wrote the paper. SW, LZ and XM reviewed and edited the manuscript. All authors read and approved the manuscript.

Ethical approval and consent to participate

The study was approved by the Ethics Committee of Zhejiang Provincial People's Hospital and all patients provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Ghouri YA, Mian I and Rowe JH: Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *J Carcinog* 16: 1, 2017.
- Altekruse SF, Henley SJ, Cucinelli JE and McGlynn KA: Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. *Am J Gastroenterol* 109: 542-553, 2014.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: E359-E386, 2015.
- Tsai WC, Kung PT, Wang YH, Kuo WY and Li YH: Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer. *PLoS One* 13: e0199532, 2018.
- Ronot M, Clift AK, Vilgrain V and Frilling A: Functional imaging in liver tumours. *J Hepatol* 65: 1017-1030, 2016.
- Marrero JA, Ahn J and Rajender Reddy K: American College of Gastroenterology: ACG clinical guideline: The diagnosis and management of focal liver lesions. *Am J Gastroenterol* 109: 1328-1348, 2014.
- Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, Chernyak V, Bashir MR, Kono Y, Do RK, *et al*: 2017 version of LI-RADS for CT and MR Imaging: An update. *Radiographics* 37: 1994-2017, 2017.
- Ryerson AB, Ehemann CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, *et al*: Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. *Cancer* 122: 1312-1337, 2016.
- Sia D, Villanueva A, Friedman SL and Llovet JM: Liver cancer cell of origin, molecular class, and effects on patient prognosis. *Gastroenterology* 152: 745-761, 2017.
- Bhoori S and Mazzaferro V: Current challenges in liver transplantation for hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol* 28: 867-879, 2014.
- Chen W, Fan W, Ru G, Huang F, Lu X, Zhang X, Mou X and Wang S: Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. *Oncol Rep* 41: 67-76, 2019.
- Staines K, Hunt LG, Young JR and Butter C: Evolution of an expanded mannose receptor gene family. *PLoS One* 9: e110330, 2014.
- Lee SH, Charmoy M, Romano A, Paun A, Chaves MM, Cope FO, Ralph DA and Sacks DL: Mannose receptor high, M2 dermal macrophages mediate nonhealing *Leishmania major* infection in a Th1 immune environment. *J Exp Med* 215: 357-375, 2018.
- Peng H, Geil Nickell CR, Chen KY, McClain JA and Nixon K: Increased expression of M1 and M2 phenotypic markers in isolated microglia after four-day binge alcohol exposure in male rats. *Alcohol* 62: 29-40, 2017.
- Salmi M, Karikoski M, Elima K, Rantakari P and Jalkanen S: CD44 binds to macrophage mannose receptor on lymphatic endothelium and supports lymphocyte migration via afferent lymphatics. *Circ Res* 112: 1577-1582, 2013.
- van Lessen M, Shibata-Germanos S, van Impel A, Hawkins TA, Rihel J and Schulte-Merker S: Intracellular uptake of macromolecules by brain lymphatic endothelial cells during zebrafish embryonic development. *Elife* 6: pii: e25932, 2017.
- Azad AK, Rajaram MV, Metz WL, Cope FO, Blue MS, Vera DR and Schlesinger LS: γ -Tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). *J Immunol* 195: 2019-2029, 2015.
- Andersen MN, Andersen NF, Rodgaard-Hansen S, Hokland M, Abildgaard N and Moller HJ: The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma. *Leuk Res* 39: 971-975, 2015.
- Bianchi G and Munshi NC: Pathogenesis beyond the cancer clone(s) in multiple myeloma. *Blood* 125: 3049-3058, 2015.
- Kume H, Muraoka S, Kuga T, Adachi J, Narumi R, Watanabe S, Kuwano M, Kodera Y, Matsushita K, Fukuoka J, *et al*: Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis. *Mol Cell Proteomics* 13: 1471-1484, 2014.
- Rodgaard-Hansen S, Rafique A, Christensen PA, Maniecki MB, Sandahl TD, Nexø E and Moller HJ: A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. *Clin Chem Lab Med* 52: 453-461, 2014.
- Sun C, Shui B, Zhao W, Liu H, Li W, Lee JC, Doran R, Lee FK, Sun T, Shen QS, *et al*: Central role of IP3R2-mediated Ca^{2+} oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor. *Cell Death Dis* 10: 396, 2019.
- Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, Yang X, Shen B and Zhang J: RACK1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing nanog. *Theranostics* 9: 811-828, 2019.
- Yang X, Li S, Wang H, Chen W, Mou X and Wang S: Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients. *Oncol Lett* 17: 2485-2490, 2019.
- Petrizzo A and Buonaguro L: Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. *J Immunother Cancer* 4: 71, 2016.
- Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Zarghampour M, Khoshpour P, Ameli S, Li Z, Hu D and Kamel IR: Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. *Eur Radiol*: Mar 15, 2019 doi: 10.1007/s00330-019-06100-3 (Epub ahead of print).
- Colecchia A, Scaiola E, Montrone L, Vestito A, Di Biase AR, Pieri M, D'Errico-Grigioni A, Bacchi-Reggiani ML, Ravaioli M, Grazi GL and Festi D: Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. *J Hepatol* 54: 300-305, 2011.
- Kong M and Hong SE: Optimal follow-up duration for evaluating objective response to radiotherapy in patients with hepatocellular carcinoma: A retrospective study. *Chin J Cancer* 34: 79-85, 2015.

29. Gan W, Zhang MX, Wang JX, Fu YP, Huang JL, Yi Y, Jing CY, Fan J, Zhou J and Qiu SJ: Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: A prognostic nomogram study. *Cancer Manag Res* 10: 5383-5394, 2018.
30. Couri T and Pillai A: Goals and targets for personalized therapy for HCC. *Hepatol Int* 13: 125-137, 2019.
31. Zhu R, Huang H, Zhang H, Wang Z, Hu X, Zhai W, Lin Y, Wang J and Zhu H: Prognostic analysis in chronic hepatitis B patients: A retrospective study of 216 cases about Scheuer scores, in situ expression of viral antigens and tissue hepatitis B virus DNA levels. *Liver Int* 26: 82-89, 2006.
32. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, *et al*: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 20: 282-296, 2019.
33. Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC, Chung YH and Lee YS: Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. *Ann Surg Oncol* 19: 3687-3696, 2012.
34. Zhong M, Zhong C, Cui W, Wang G, Zheng G, Li L, Zhang J, Ren R, Gao H, Wang T, *et al*: Induction of tolerogenic dendritic cells by activated TGF-beta/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells. *BMC Cancer* 19: 439, 2019.
35. Wei X, You X, Zhang J and Zhou C: MicroRNA-1305 inhibits the stemness of LCSCs and Tumorigenesis by repressing the UBE2T-dependent Akt-signaling pathway. *Mol Ther Nucleic Acids* 16: 721-732, 2019.
36. Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, Chao TY and Yeh CT: HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. *Exp Cell Res* 370: 519-530, 2018.
37. Choi HS, Kim JH, Kim SL, Deng HY, Lee D, Kim CS, Yun BS and Lee DS: Catechol derived from aronia juice through lactic acid bacteria fermentation inhibits breast cancer stem cell formation via modulation Stat3/IL-6 signaling pathway. *Mol Carcinog* 57: 1467-1479, 2018.
38. Mani SK, Zhang H, Diab A, Pascuzzi PE, Lefrancois L, Fares N, Bancel B, Merle P and Andrisani O: EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. *J Hepatol* 65: 888-898, 2016.
39. Liu M, Jiang L and Guan XY: The genetic and epigenetic alterations in human hepatocellular carcinoma: A recent update. *Protein Cell* 5: 673-691, 2014.
40. Orcutt ST and Anaya DA: Liver resection and surgical strategies for management of primary liver cancer. *Cancer Control* 25: 1073274817744621, 2018.
41. Scodeller P, Simon-Gracia L, Kopanchuk S, Tobi A, Kilk K, Saalik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, *et al*: Precision targeting of tumor macrophages with a CD206 binding peptide. *Sci Rep* 7: 14655, 2017.
42. Maehara O, Ohnishi S, Asano A, Suda G, Natsuzaka M, Nakagawa K, Kobayashi M, Sakamoto N and Takeda H: Metformin regulates the expression of CD133 through the AMPK-CEBP β pathway in hepatocellular carcinoma cell lines. *Neoplasia* 21: 545-556, 2019.
43. Palla AR, Piazzolla D, Abad M, Li H, Dominguez O, Schonhaler HB, Wagner EF and Serrano M: Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer. *Oncogene* 33: 2513-2519, 2014.
44. Jerabek S, Merino F, Scholer HR and Cojocaru V: OCT4: Dynamic DNA binding pioneers stem cell pluripotency. *Biochim Biophys Acta* 1839: 138-154, 2014.
45. Guvench O: Revealing the mechanisms of protein disorder and N-glycosylation in CD44-hyaluronan binding using molecular simulation. *Front Immunol* 6: 305, 2015.
46. Yoshida GJ: Emerging roles of Myc in stem cell biology and novel tumor therapies. *J Exp Clin Cancer Res* 37: 173, 2018.
47. Suzuki Y, Haraguchi N, Takahashi H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Ishii H, Doki Y, *et al*: SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers. *Int J Oncol* 42: 161-167, 2013.
48. Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H, Zhu S, Savitt AG, Rowehl RA, Leyfman Y, Ju J, *et al*: New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. *Mol Cancer* 9: 192, 2010.
49. Kanda T, Goto T, Hirotsu Y, Moriyama M and Omata M: Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic Hepatitis B and C infections: A review. *Int J Mol Sci* 20: pii: E1358, 2019.
50. Zahra M, Azzazy H and Moustafa A: Transcriptional regulatory networks in Hepatitis C virus-induced hepatocellular carcinoma. *Sci Rep* 8: 14234, 2018.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.